191 related articles for article (PubMed ID: 31744428)
1. Antipsychotic Medication Adherence and Diabetes-Related Hospitalizations Among Medicaid Recipients With Diabetes and Schizophrenia.
Egglefield K; Cogan L; Leckman-Westin E; Finnerty M
Psychiatr Serv; 2020 Mar; 71(3):236-242. PubMed ID: 31744428
[TBL] [Abstract][Full Text] [Related]
2. Adherence to antipsychotics and cardiometabolic medication: association with health care utilization and costs.
Hansen RA; Maciejewski M; Yu-Isenberg K; Farley JF
Psychiatr Serv; 2012 Sep; 63(9):920-8. PubMed ID: 22706887
[TBL] [Abstract][Full Text] [Related]
3. Rates and predictors of antipsychotic non-adherence and hospitalization in Medicaid and commercially-insured patients with schizophrenia.
Lang K; Federico V; Muser E; Menzin J; Menzin J
J Med Econ; 2013 Aug; 16(8):997-1006. PubMed ID: 23777223
[TBL] [Abstract][Full Text] [Related]
4. Prospective validation of eight different adherence measures for use with administrative claims data among patients with schizophrenia.
Karve S; Cleves MA; Helm M; Hudson TJ; West DS; Martin BC
Value Health; 2009 Sep; 12(6):989-95. PubMed ID: 19402852
[TBL] [Abstract][Full Text] [Related]
5. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia.
Gilmer TP; Dolder CR; Lacro JP; Folsom DP; Lindamer L; Garcia P; Jeste DV
Am J Psychiatry; 2004 Apr; 161(4):692-9. PubMed ID: 15056516
[TBL] [Abstract][Full Text] [Related]
6. Use of a Web-Based Shared Decision-Making Program: Impact on Ongoing Treatment Engagement and Antipsychotic Adherence.
Finnerty MT; Layman DM; Chen Q; Leckman-Westin E; Bermeo N; Ng-Mak DS; Rajagopalan K; Hoagwood KE
Psychiatr Serv; 2018 Dec; 69(12):1215-1221. PubMed ID: 30286709
[TBL] [Abstract][Full Text] [Related]
7. Adherence to Antipsychotic Therapy: Association With Hospitalization and Medicare Spending Among Part D Enrollees With Schizophrenia.
Roberto P; Brandt N; Onukwugha E; Perfetto E; Powers C; Stuart B
Psychiatr Serv; 2017 Nov; 68(11):1185-1188. PubMed ID: 28760097
[TBL] [Abstract][Full Text] [Related]
8. Medication adherence and hospitalization among patients with schizophrenia treated with antipsychotics.
Lang K; Meyers JL; Korn JR; Lee S; Sikirica M; Crivera C; Dirani R; Menzin J
Psychiatr Serv; 2010 Dec; 61(12):1239-47. PubMed ID: 21123409
[TBL] [Abstract][Full Text] [Related]
9. One-Year Medication Treatment Patterns, Healthcare Resource Utilization, and Expenditures for Medicaid Patients with Schizophrenia Starting Oral Atypical Antipsychotic Medication.
Richards K; Johnsrud M; Zacker C; Sasané R
Adm Policy Ment Health; 2024 Mar; 51(2):207-216. PubMed ID: 38071724
[TBL] [Abstract][Full Text] [Related]
10. Antipsychotic medication adherence and preventive diabetes screening in Medicaid enrollees with serious mental illness: an analysis of real-world administrative data.
Stockbridge EL; Webb NJ; Dhakal E; Garg M; Loethen AD; Miller TL; Nandy K
BMC Health Serv Res; 2021 Jan; 21(1):69. PubMed ID: 33461561
[TBL] [Abstract][Full Text] [Related]
11. Trends in and Predictors of Long-Term Antipsychotic Polypharmacy Use Among Ohio Medicaid Patients with Schizophrenia, 2008-2014.
Fontanella CA; Hiance-Steelesmith DL; Guirgis H; Campo JV
Psychiatr Serv; 2018 Sep; 69(9):1015-1020. PubMed ID: 29962308
[TBL] [Abstract][Full Text] [Related]
12. Changes over time and disparities in schizophrenia treatment quality.
Busch AB; Lehman AF; Goldman H; Frank RG
Med Care; 2009 Feb; 47(2):199-207. PubMed ID: 19169121
[TBL] [Abstract][Full Text] [Related]
13. Impact of early nonadherence to oral antipsychotics on clinical and economic outcomes among patients with schizophrenia.
Offord S; Lin J; Mirski D; Wong B
Adv Ther; 2013 Mar; 30(3):286-97. PubMed ID: 23483449
[TBL] [Abstract][Full Text] [Related]
14. Examining quality of care for individuals treated for mental health using the HEDIS mental health quality measures.
Ng-Mak D; Rajagopalan K
Curr Med Res Opin; 2019 Jan; 35(1):87-95. PubMed ID: 30286663
[No Abstract] [Full Text] [Related]
15. Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.
Pilon D; Tandon N; Lafeuille MH; Kamstra R; Emond B; Lefebvre P; Joshi K
Clin Ther; 2017 Oct; 39(10):1972-1985.e2. PubMed ID: 28919292
[TBL] [Abstract][Full Text] [Related]
16. Continuity of antipsychotic medication management for Medicaid patients with schizophrenia.
Farley JF; Wang CC; Hansen RA; Voils CI; Maciejewski ML
Psychiatr Serv; 2011 Jul; 62(7):747-52. PubMed ID: 21724787
[TBL] [Abstract][Full Text] [Related]
17. Antipsychotic adherence patterns and health care utilization and costs among patients discharged after a schizophrenia-related hospitalization.
Markowitz M; Karve S; Panish J; Candrilli SD; Alphs L
BMC Psychiatry; 2013 Oct; 13():246. PubMed ID: 24094241
[TBL] [Abstract][Full Text] [Related]
18. Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder.
Greene M; Yan T; Chang E; Hartry A; Touya M; Broder MS
J Med Econ; 2018 Feb; 21(2):127-134. PubMed ID: 28895758
[TBL] [Abstract][Full Text] [Related]
19. "Impact of drug-reimbursement policies on prescribing: A case-study of a newly marketed long-acting injectable antipsychotic among relapsed schizophrenia patients".
Jackson JW; Fulchino L; Rogers J; Mogun H; Polinski J; Henderson DC; Schneeweiss S; Fischer MA
Pharmacoepidemiol Drug Saf; 2018 Jan; 27(1):95-104. PubMed ID: 29168261
[TBL] [Abstract][Full Text] [Related]
20. Atypical antipsychotic adherence is associated with lower inpatient utilization and cost in bipolar I disorder.
Broder MS; Greene M; Chang E; Hartry A; Yan T; Yermilov I
J Med Econ; 2019 Jan; 22(1):63-70. PubMed ID: 30376745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
